Posaconazole (Noxafil) is an anti-fungal drug that can be used to treat a wide range of fungal infections. It is available as an oral suspension and is manufactured by Schering-Plough. It was approved in the European Union in October 2005.

Posaconazole is an effective treatment for thrush in the mouth in patients with HIV or AIDS. A recent study has shown that is as effective as the standard systemic drug fluconazole (Diflucan) but that it has a lower risk of relapse.1 It may also be effective for cryptococcal meningitis and other fungal infections of the brain and spinal cord.2


  1. Vazquez JA et al. A multicentre randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV / AIDS. Clin Infect Dis 42: 1179-1186, 2006
  2. Pitisuttithum P et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56: 745-755, 2005

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.